NASDAQ:IRTCIrhythm Technologies Stock Price, Forecast & News

Irhythm Technologies' stock was trading at $85.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IRTC stock has increased by 40.4% and is now trading at $120.09. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Irhythm Technologies in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Irhythm Technologies.

Irhythm Technologies is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Irhythm Technologies.

Irhythm Technologies Inc (NASDAQ:IRTC) announced its earnings results on Thursday, May, 7th. The company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.57) by $0.23. The firm earned $63.50 million during the quarter, compared to analysts' expectations of $61.40 million. Irhythm Technologies had a negative return on equity of 49.99% and a negative net margin of 24.34%. The business's revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.33) EPS. View Irhythm Technologies' earnings history.

Irhythm Technologies updated its first quarter 2020 After-Hours earnings guidance on Thursday, April, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $61-62 million, compared to the consensus revenue estimate of $60.67 million.

8 analysts have issued 12 month target prices for Irhythm Technologies' shares. Their forecasts range from $112.00 to $142.00. On average, they anticipate Irhythm Technologies' share price to reach $130.67 in the next twelve months. This suggests a possible upside of 8.8% from the stock's current price. View analysts' price targets for Irhythm Technologies.

Media headlines about IRTC stock have trended positive on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Irhythm Technologies earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutIrhythm Technologies.

Some companies that are related to Irhythm Technologies include Insulet (PODD), ABIOMED (ABMD), Hill-Rom (HRC), Novocure (NVCR), Penumbra (PEN), Globus Medical (GMED), Haemonetics (HAE), Tandem Diabetes Care (TNDM), Integra Lifesciences (IART), Nevro (NVRO), ICU Medical (ICUI), NuVasive (NUVA), Merit Medical Systems (MMSI), Inspire Medical Systems (INSP) and Cantel Medical (CMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Irhythm Technologies investors own include Alibaba Group (BABA), NVIDIA (NVDA), DexCom (DXCM), Paypal (PYPL), Teladoc Health (TDOC), Shopify (SHOP), Veeva Systems (VEEV), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Paycom Software (PAYC).

(IRTC) raised $76 million in an IPO on Thursday, October 20th 2016. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers.

Irhythm Technologies trades on the NASDAQ under the ticker symbol "IRTC."

Irhythm Technologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (12.19%), BlackRock Inc. (7.82%), Alliancebernstein L.P. (6.25%), William Blair Investment Management LLC (5.30%), Capital Research Global Investors (5.01%) and JPMorgan Chase & Co. (4.98%). Company insiders that own Irhythm Technologies stock include Bruce G Bodaken, David A Vort, Derrick Sung, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, Ralph Snyderman and Raymond W Scott. View institutional ownership trends for Irhythm Technologies.

IRTC stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Wellington Management Group LLP, BlackRock Inc., Massachusetts Financial Services Co. MA, Deutsche Bank AG, Squarepoint Ops LLC, Brown Capital Management LLC, and Aigen Investment Management LP. Company insiders that have sold Irhythm Technologies company stock in the last year include David A Vort, Kevin M King, Matthew C Garrett, Merz Cathleen Noel Bairey, and Ralph Snyderman. View insider buying and selling activity for Irhythm Technologies.

IRTC stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Invesco Ltd., William Blair Investment Management LLC, Loomis Sayles & Co. L P, Fiera Capital Corp, Lord Abbett & CO. LLC, Balyasny Asset Management LLC, and Morgan Stanley. View insider buying and selling activity for Irhythm Technologies.

Shares of IRTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of IRTC stock can currently be purchased for approximately $120.09.

Irhythm Technologies has a market capitalization of $3.25 billion and generates $214.55 million in revenue each year. The company earns $-54,570,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Irhythm Technologies employs 748 workers across the globe.

The official website for Irhythm Technologies is www.irhythmtech.com.

Irhythm Technologies' mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company can be reached via phone at 415-632-5700 or via email at [email protected]